AM-411
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| Identifiers | |
| PubChem | CID 9799945 |
| ChemSpider |
7975710  |
| ChEMBL |
CHEMBL434351 |
| Chemical data | |
| Formula | C26H34O2 |
| Molar mass | 378.546 g/mol |
| |
| |
| (verify) | |
AM-411 is an analgesic drug that is a cannabinoid agonist. It is a derivative of Δ8THC substituted with an adamantyl group at the 3-position, demonstrating that the binding pocket for the alkyl chain at this position can accommodate significant bulk.
AM-411 is a potent and fairly selective CB1 full agonist with a Ki of 6.80nM, but is still also a moderately potent CB2 agonist with a Ki of 52.0nM.[1] It produces similar effects to other cannabinoid agonists such as analgesia, sedation, and anxiolysis.[2][3]
See also
References
- ↑ Lu D, et al. Adamantyl cannabinoids: a novel class of cannabinergic ligands. Journal of Medicinal Chemistry. 2005 Jul 14;48(14):4576-85. PMID 15999995
- ↑ Järbe TU, DiPatrizio NV, Lu D, Makriyannis A. (−)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behavioural Pharmacology. 2004 Nov;15(7):517-21. PMID 15472574
- ↑ McLaughlin PJ, et al. Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacology, Biochemistry and Behaviour. 2005 May;81(1):78-88. PMID 15894067
This article is issued from Wikipedia - version of the Sunday, February 08, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.